Sanctuary Advisors LLC Reduces Stake in Galectin Therapeutics Sanctuary Advisors LLC has sold 20,700 shares of Galectin Therapeutics, reducing its stake by 26.2% during the fourth quarter. This transaction left the firm with 58,413 shares, valued at $73,000. The move reflects broader trends as other institutional investors also adjusted their holdings in the biopharmaceutical company.1